Omalizumab for food allergy.

PURPOSE OF REVIEW: Omalizumab was approved by the U.S. Food and Drug Administration (FDA) to reduce allergic reactions from accidental exposures to food allergens in 2024. This review examines the current state of play including the most relevant studies supporting this approval and ongoing research regarding the use of omalizumab for food Allergy.

RECENT FINDINGS: The OUtMATCH trial demonstrated omalizumab's effectiveness in increasing the reaction threshold to multiple foods in patients with multiple food allergy. New evidence from stage 3 of OUtMATCH suggests that omalizumab can further allow dietary consumption of allergenic foods. Ongoing studies are evaluating omalizumab's role compared to oral immunotherapy (OIT) and in combination with OIT.

SUMMARY: Omalizumab represents an important treatment option for patients and families affected by food allergy. Significant progress has been made in understanding the drug's effects as a monotherapy and as an adjunct to OIT. As new evidence continues to emerge, the optimal use of omalizumab in managing food allergy will be further clarified.